Aspirin Twice Daily in Diabetic Patients With Coronary Artery Disease
Aspirin Twice Daily in Diabetic Patients With Coronary Artery Disease
The aim of the study is to evaluate platelet function variations according to the delay since
 last aspirin intake (12 vs 24 hours)in a population of diabetic patients with previous
 Coronary Artery Disease.
We have previously demonstrated that there was a time-dependant efficacy of aspirin on
 platelet function. In this study, we investigate platelet function (fundamental research)
 according to the delay since last aspirin intake (12 vs 24 hours)in a population of diabetic
 patients with previous Coronary Artery Disease routinely treated with aspirin. In order to
 eliminate any variation linked to a cumulative dose effect of aspirn, platelet function is
 assessed 24 hours after a single 150 mg aspirin intake or 12 hours after a 75 mg aspirin
 intake given twice per day (corresponding to the same total dose of 150 mg /day). Light
 transmission aggregometry triggered by arachidonic acid 0.5mg/mL (LTA-AA) is the main
 endpoint of the study (intensity and velocity of agregation following exposure to arachidonic
 acid 0.5 mg/ml).
Inclusion Criteria:

 -  type 2 diabetes mellitus

 -  documented coronary artery disease

 -  treatment with aspirin for at least 7 days before randomization

 -  one of the following additional criteria defined from our previous study9: current
 smoking, hs-CRP > 4mg/L, fibrinogen > 4g/L and/or platelet count > 270 103/mm3

 Exclusion Criteria:

 -  oral anticoagulants, heparin, thrombolytic agents, non-steroidal anti-inflammatory
 drugs, prasugrel

 -  family or personal history of bleeding or thrombophilic disorders

 -  platelet count > 600x103/mm3 or < 150x103/mm3

 -  hematocrit > 50% or < 25%

 -  creatinine clearance < 30mL/min

 -  low compliance before enrollment

 -  cancer considered not in remission or those having undergone major surgery within the
 month prior to enrollment.